Purpose | Dosage Range | Frequency | Administration |
---|---|---|---|
Fat Loss | 250-500 mcg | 1-2x daily | Subcutaneous injection |
Research | 25-1000 mcg | As per protocol | Subcutaneous injection |
Performance Enhancement | 300-500 mcg | 1-2x daily | Subcutaneous injection |
2. What is Frag 176-191?
Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Molecular formula: C78H125N23O23S2
Molecular weight: 1815.1 g/mol
Synthetic peptide comprising amino acids 176-191 of the HGH molecule
Developed to isolate the fat-burning effects of HGH without other growth-promoting effects
Stimulates lipolysis (breakdown of fat)
Inhibits lipogenesis (formation of fat)
Increases fat oxidation
May enhance glucose metabolism
Potentially influences insulin-like growth factor-1 (IGF-1) production
Affects gene expression related to fat metabolism
May have localized effects on adipose tissue
Promotes reduction in body fat percentage
May be particularly effective for stubborn fat areas
Potential for targeted fat loss when used locally
Enhances metabolic rate
May improve insulin sensitivity
Potential benefits for overall metabolic health
Possible improvements in endurance and recovery
May support lean muscle maintenance during fat loss phases
Some studies suggest potential benefits for cartilage regeneration
May have applications in joint health and repair
Potential skin rejuvenation effects
May contribute to overall body composition improvement
Typical dose: 250-500 mcg
Administered 1-2 times daily, preferably on an empty stomach
Dose range: 250-1000 mcg
Frequency depends on specific research protocol
Typical dose: 300-500 mcg
Administered 1-2 times daily, often pre-workout and/or before bed
Reconstitute lyophilized Frag 176-191 with bacteriostatic water
Use sterile injection materials
Calculate dosage based on concentration (e.g., 5 mg/ml)
Draw correct amount into insulin syringe
Administer via subcutaneous injection
Most common and effective method
Inject into fatty tissue of abdomen, thigh, or love handles
Rotate injection sites to prevent irritation
Less common and likely less effective
Some experimental use in creams or gels for localized fat loss
Potential synergistic effects on fat loss and metabolism
May enhance overall body composition improvements
Combination used by some for enhanced fat loss and endurance
Caution advised due to limited safety data on this combination
Injection site reactions
Temporary water retention
Potential changes in blood sugar levels
Not approved by the FDA for human use
Legal status varies by country and jurisdiction
Often restricted to research or medical use
In the US, it's legal to possess for research purposes but not for human consumption
Banned by WADA for competitive athletes
Store lyophilized powder at -20°C (-4°F)
Once reconstituted, store in refrigerator (2-8°C or 36-46°F)
Use within 30 days after reconstitution
Protect from light and excessive heat
Always use sterile techniques when handling
Results may vary, but some users report noticeable fat loss within 4-6 weeks of consistent use.
While not primarily designed for muscle growth, it may be used in cutting phases for fat loss while preserving lean mass.
Unlike full HGH, Frag 176-191 is not believed to significantly impact overall growth hormone levels.
Frag 176-191 offers a more targeted approach to fat loss compared to many traditional supplements, potentially with fewer systemic effects.
Frag 176-191 shows promise as a targeted fat loss peptide with potential benefits for body composition and metabolism. The typical dosage range of 250-500 mcg administered 1-2 times daily appears effective for most research applications. Its ability to promote fat loss without significantly affecting other growth hormone functions makes it an intriguing subject for further study.However, its use should be approached cautiously due to limited long-term human safety data and varying legal status worldwide. As with any experimental compound, thorough research and professional consultation are essential before use. The potential of Frag 176-191 in fat loss, metabolic health, and potentially cartilage repair warrants further investigation, particularly in larger, long-term human trials.
Heffernan MA, et al. (2000). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology, 141(7), 2552-2562.
Ng FM, et al. (2000). Metabolic effects of DAG(904-914), a fragment of human growth hormone. Hormone Research, 53(6), 274-278.
Stier H, et al. (2004). AOD9604 and its derivatives - novel lipolytic domain peptides. Anti-Obesity Drug Discovery and Development, 1(1), 73-83.
Jiang G, Zhang BB. (2002). Glucagon and regulation of glucose metabolism. American Journal of Physiology-Endocrinology and Metabolism, 283(4), E671-E678.
Ehrenborg E, Krook A. (2009). Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor δ. Pharmacological Reviews, 61(3), 373-393.
Disclaimer
Peptideresearcher.com contains information about products intended for research and laboratory use only, unless otherwise explicitly stated. All content is for educational purposes and is not meant to substitute for professional medical advice. Peptideresearcher.com strives to ensure that all information presented is accurate and complies with national and international standards, but it is not guaranteed. The content provided is not intended to diagnose, treat, cure, or prevent any disease or condition.
Peptideresearcher.com does not offer medical diagnoses or prescriptions. Any product information shared is solely for research purposes and should be used by qualified professionals only. We advise all users to consult with a healthcare professional before using any peptides, supplements, or medications mentioned on this site. All opinions expressed are those of the individual authors and may not reflect the opinions of Peptideresearcher.com.
Copyright 2024 - Peptide Researcher
Your access to Peptideresearcher.com is subject to our Terms of Use